title: Anti-HI can cause a severe delayed hemolytic transfusion reaction with hyperhemolysis in sickle cell disease patients.
abstract: Delayed hemolytic transfusion reaction (DHTR) is a life-threatening condition in sickle cell disease (SCD) patients that is frequently complicated by hyperhemolysis. Antibodies resulting from antigen disparity between donors of European ancestry and patients of African ancestry are common, but situations involving antibodies not classically of clinical significance are also encountered. Anti-HI is generally considered to be an innocuous naturally occurring antibody.
  
  
  
  We describe two cases of hyperhemolysis with anti-HI and provide details of the reported cases.
  
  
  
  Both SCD patients were polyimmunized and belonged to blood group B. They developed anti-HI that was reactive at 37°C, after the transfusion of group O red blood cell units matched for all known and produced antibodies classically considered to be clinically significant. Both patients developed DHTR with hyperhemolysis. In the first case, a pregnant woman, a second transfusion was unavoidable and the patient died from cardiac arrest. The state of the second patient improved without the need for further transfusion.
  
  
  
  Three other cases of DHTR with anti-HI have been described in the literature in SCD patients. The two additional cases reported here definitively demonstrate that anti-HI is dangerous in SCD patients. As a result, ABO-identical matching (including A1 status) must be considered in SCD patients with anti-HI.
authors.affiliation: Établissement Français du Sang, Ile de France, Hôpital Henri Mondor.
authors.forename: Clara
authors.initials: C
authors.lastname: Ibanez
authors.affiliation: IMRB, INSERM U955, Equipe 2: Transfusion et maladies du globule rouge, Institut Mondor de Recherche Biomédicale, UPEC, Créteil, France.|Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri Mondor, AP-HP, UPEC, Créteil.|Laboratoire D'Excellence GR-Ex, F-75015 Paris, France.
authors.forename: Anoosha
authors.initials: A
authors.lastname: Habibi
authors.affiliation: Service de Réanimation Médicale, Hôpital Henri Mondor, AP-HP, UPEC.
authors.forename: Armand
authors.initials: A
authors.lastname: Mekontso-Dessap
authors.affiliation: Établissement Français du Sang, Ile de France, Hôpital Henri Mondor.|IMRB, INSERM U955, Equipe 2: Transfusion et maladies du globule rouge, Institut Mondor de Recherche Biomédicale, UPEC, Créteil, France.|Laboratoire D'Excellence GR-Ex, F-75015 Paris, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Chadebech
authors.affiliation: Établissement Français du Sang, Ile de France, Hôpital Henri Mondor.
authors.forename: Btissam
authors.initials: B
authors.lastname: Chami
authors.affiliation: Établissement Français du Sang, Ile de France, Hôpital Henri Mondor.|IMRB, INSERM U955, Equipe 2: Transfusion et maladies du globule rouge, Institut Mondor de Recherche Biomédicale, UPEC, Créteil, France.
authors.forename: Philippe
authors.initials: P
authors.lastname: Bierling
authors.affiliation: IMRB, INSERM U955, Equipe 2: Transfusion et maladies du globule rouge, Institut Mondor de Recherche Biomédicale, UPEC, Créteil, France.|Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri Mondor, AP-HP, UPEC, Créteil.|Laboratoire D'Excellence GR-Ex, F-75015 Paris, France.
authors.forename: Frédéric
authors.initials: F
authors.lastname: Galactéros
authors.affiliation: Unité de Sécurité Transfusionnelle et d'Hémovigilance, Hôpital Henri Mondor, AP-HP, Créteil, France.
authors.forename: Claire
authors.initials: C
authors.lastname: Rieux
authors.affiliation: Institut National de la Transfusion Sanguine, Département Centre National de référence pour les Groupes Sanguins.
authors.forename: Joëlle
authors.initials: J
authors.lastname: Nataf
authors.affiliation: IMRB, INSERM U955, Equipe 2: Transfusion et maladies du globule rouge, Institut Mondor de Recherche Biomédicale, UPEC, Créteil, France.|Centre de Référence des Syndromes Drépanocytaires Majeurs, Hôpital Henri Mondor, AP-HP, UPEC, Créteil.|Laboratoire D'Excellence GR-Ex, F-75015 Paris, France.
authors.forename: Pablo
authors.initials: P
authors.lastname: Bartolucci
authors.affiliation: Laboratoire D'Excellence GR-Ex, F-75015 Paris, France.|Institut National de la Transfusion Sanguine, Département Centre National de référence pour les Groupes Sanguins.|INSERM UMR_S1134, F-75015 Paris, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Peyrard
authors.affiliation: Établissement Français du Sang, Ile de France, Hôpital Henri Mondor.|IMRB, INSERM U955, Equipe 2: Transfusion et maladies du globule rouge, Institut Mondor de Recherche Biomédicale, UPEC, Créteil, France.|Laboratoire D'Excellence GR-Ex, F-75015 Paris, France.
authors.forename: France
authors.initials: F
authors.lastname: Pirenne
mesh_terms: D000017:ABO Blood-Group System / Q000276:immunology; D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000628:therapy; D001787:Blood Group Incompatibility / Q000276:immunology*; D017809:Fatal Outcome; D005260:Female; D006461:Hemolysis / Q000276:immunology*; D006801:Humans; D007518:Isoantibodies / Q000494:pharmacology; D011247:Pregnancy; D013997:Time Factors; D065227:Transfusion Reaction / Q000473:pathology*
chemical_list: D000017:ABO Blood-Group System; D007518:Isoantibodies